Repligen (RGEN)Artemis Investment Management LLP reduced its stake -300K shares
Artemis Investment Management LLP reduced its stake in Repligen, per its Q2 2026 13F.
- 122K
- Shares reported · -300K vs prior quarter
- 0.15%
- Disclosed portfolio weight
- $16.6M
- Reported value
- Holdings as of
- Jun 30, 2026
- Filed
- Jul 23, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 28, 2026Federal contract · $175K obligatedDepartment of Health and Human Services awarded REPLIGEN CORP: $175K obligated to date
- Jun 25, 2026InsiderCFO sold ~$106K of RGEN shares in the open market
- Jul 16, 2026InsiderCFO sold ~$80K of RGEN shares in the open market
- Jul 21, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)
What came next
- Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 20, 2026InsiderCEO sold ~$977K of RGEN shares in the open market
- Sep 1, 2026Federal contract · $169K obligatedDepartment of Agriculture awarded REPLIGEN CORP: $169K obligated to date
- Sep 4, 2026InsiderCEO sold ~$504K of RGEN shares in the open market
- Sep 10, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of September 30, 2026.”
- Sep 21, 2026InsiderCEO sold ~$977K of RGEN shares in the open market
- Sep 24, 2026Insider · 1 personInsiders: 2 sales (~$2.5M)
- Oct 5, 2026Insider · 1 personInsiders: 2 sales (~$1.0M)
- Oct 6, 2026Company filing · Form 8-K · Acquisition or sale, Reg FDCompleted buying or selling a business or assets, and shared information with investors“The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this”
- Oct 7, 20265% stakeFMR LLC reported a passive stake (13G) of 13.0%
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Repligen
For Repligen, OQRO holds 10 insider filings (SEC Form 4 or Form 144), 15 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RGEN page.
How this filing works
Other disclosures at Repligen
- SEC Form 4Oct 6, 2026
- SEC Form 4Oct 6, 2026
- SEC Form 144Oct 5, 2026
- SEC Form 144Oct 5, 2026
- SEC Form 4Sep 26, 2026
- SEC Form 4Sep 26, 2026
Everything OQRO holds on this company is on its RGEN page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
